Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial

The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral resid...

Descripción completa

Detalles Bibliográficos
Autores: Puig, Noemí|||0000-0001-7535-3861, Agulló, Cristina, Contreras, Teresa, Pérez, José Juan, Aires, Irene, Calasanz, M.J.|||0000-0002-0374-3008, García-Sanz, Ramón|||0000-0003-4120-2787, Castro, Sergio, Martínez-López, Joaquín|||0000-0001-7908-0063, Rodriguez-Otero, Paula|||0000-0001-5236-7785, González-Calle, Verónica|||0000-0002-5493-6707, González, Marta S., Oriol, Albert|||0000-0001-6804-2221, Gutierrez, Norma|||0000-0001-5834-9510, Ríos-Tamayo, Rafael|||0000-0001-8193-1402, Rosiñol, Laura|||0000-0002-2534-9239, Álvarez, Miguel Ángel, Bargay, Joan|||0000-0002-6739-3916, Gonzalez-Rodriguez, Ana P., Alegre, Adrian|||0000-0002-2423-822X, Escalante, Fernando|||0000-0003-4501-9066, Iñigo Rodríguez, María Belén, de la Rubia, Javier|||0000-0002-8354-768X, Teruel, Ana Isabel|||0000-0003-1559-7607, De Arriba, Felipe|||0000-0002-4451-1318, Palomera, Luis|||0000-0003-0359-7191, Hernández, Miguel Teodoro|||0000-0002-6576-7881, López-Jiménez, Javier, Reinoso, Marta, García-Mateo, Aránzazu, Ocio, Enrique M.|||0000-0002-5765-0085, Bladé Creixenti, Juan|||0000-0002-4563-3405, Lahuerta, J. J.|||0000-0002-3393-9570, Cedena, María Teresa|||0000-0001-5851-3720, Paiva, Bruno|||0000-0003-1977-3815, San Miguel, Jesús F., Mateos, M. V.|||0000-0003-2390-1218
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:311095
Acceso en línea:https://ddd.uab.cat/record/311095
https://dx.doi.org/urn:doi:10.3324/haematol.2024.285742
Access Level:acceso abierto
Palabra clave:Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Male
Mass Spectrometry
Middle Aged
Multiple Myeloma
Myeloma Proteins
Neoplasm, Residual
Prognosis
Smoldering Multiple Myeloma
Treatment Outcome
Descripción
Sumario:The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have, therefore, investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by next-generation flow cytometry (NGF) identified cases with a significantly shorter median progression-free survival (mPFS) (MS: not reached vs. 1.4 years, P=0.001; NGF: not reached vs. 2 years, P=0.0002) but reaching complete response (CR) + stringent CR (sCR) did not discriminate between patients with different outcome. With NGF as a reference, the combined results of NGF and MS showed a high negative predictive value (NPV) of MS: 81% overall and 73% at treatment completion. When sequential results were considered, sustained negativity by MS or NGF was associated with a very favorable outcome with an mPFS not yet reached versus 1.66 years and 2.18 years in cases never attaining PRD or minimal residual disease (MRD) negativity, respectively. We can, thus, conclude that: 1) the standard response categories of the International Myeloma Working Group do not seem to be useful for monitoring treatment in HRsMM patients; 2) MS could be used as a valuable, non-invasive, clinical tool with the capacity of guiding timely bone marrow evaluations (based on its high NPV with NGF as a reference); and 3) similarly to NGF, sequential results of MS are able to identify a subgroup of HRsMM patients with long-term disease control. This study was registered at www.clinicaltrials.gov (clinicaltrials.gov identifier: 02415413).

Similares en LA Referencia